Y-mAbs Therapeutics 2025 annual meeting results: all proposals approved

Y-mAbs Therapeutics, Inc.

David N. Gill elected Class I director: 18,926,572 for, 11,924,775 against, 3,133,377 broker non-votes.
Ratification of PwC as auditor for FY 2025: 32,884,437 for, 1,097,151 against, 3,136 abstain.
Non-binding advisory vote on executive compensation approved: 27,011,027 for, 3,838,565 against, 1,755 abstain.
Broker non-votes on Proposal 3: 3,133,377; all proposals passed as recommended.

item 5.07

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.